Medication or bariatric surgery: how do you choose?

For the first time these two treatments overlap. Medication now reaches weight loss figures that were previously achievable only with an operation, which makes this a genuine choice for many patients rather than a last resort question. The comparison is no longer surgery against nothing. It is surgery against a treatment that works well while it is taken and stops working when it is not.

What the surgical criteria say

The 2022 guidance from the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity states that surgery is recommended for individuals with a BMI above 35 kg/m2 regardless of the presence, absence or severity of comorbidities, and for patients with type 2 diabetes and a BMI above 30 kg/m2. It should be considered in those with a BMI of 30 to 34.9 who have not succeeded with non-surgical approaches. In Asian populations the thresholds are lower: clinical obesity is recognised above a BMI of 25, and surgery should be offered above 27.5. The same guidance notes that long-term data consistently demonstrate the safety, efficacy and durability of surgery.

Comparing the two honestly

Surgery still produces the larger average result and does not depend on continuing to take anything. Its costs are an operation with real perioperative risk, permanent anatomical change, lifelong micronutrient supplementation and monitoring, and a small but real rate of revisional procedures. Medication avoids all of that, and its cost is that the effect stops when the drug stops: in SURMOUNT-4, 82 percent of people who came off tirzepatide regained more than a quarter of their loss within a year.

How the decision is usually made

The 2026 ADA standards position surgery as the next step where there has been an inadequate response to obesity medication after escalation to the maximum tolerated dose or a change of agent. In practice the deciding factors are the amount of weight that needs to come off, whether type 2 diabetes is present and how long it has been present, whether you can sustain treatment indefinitely, and your own tolerance for an operation versus a weekly injection. These are not mutually exclusive: medication before surgery, and medication after surgery for inadequate loss or later regain, are both established uses.

If you are weighing this up, ask for a referral to a metabolic and bariatric surgical team for an assessment even if you are undecided. An assessment is not a commitment, and having both options costed properly in clinical terms is better than choosing between one you understand and one you have only read about.